AKTX

Akari Therapeutics, Plc NASDAQ Listed Jan 6, 2014

Healthcare ·Biotechnology ·GB · akaritx.com

$6.58

Pre-mkt $3.13 +2.29%

Mkt Cap $5.9M

52w Low $3.25 6.2% of range 52w High $56.80

50d MA $6.55 200d MA $20.20

P/E (TTM) 0.0x

EV/EBITDA -0.3x

P/B 0.2x

Debt/Equity 0.0x

ROE -61.1%

P/FCF -0.9x

RSI (14) —

ATR (14) —

Beta 0.54

50d MA $6.55

200d MA $20.20

Avg Volume 27.7K

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

SIC Code

2834

CIK (SEC)

1541157

Phone

44 20 8004 0270

75/76 Wimpole Street · London, FL W1G 9RT · GB

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 7, 2026	AMC	-1.80	-2.99	-66.1%	3.80	-0.5%	+2.1%	+1.0%	-2.3%	+11.0%	+8.9%	—
Nov 13, 2025	AMC	-0.04	-0.10	-150.0%	20.80	+7.7%	+1.7%	-10.4%	+12.0%	-6.0%	-7.3%	—
Aug 13, 2025	AMC	-0.09	-0.06	+33.3%	39.30	+1.8%	-1.3%	+4.1%	-1.0%	-0.9%	-4.2%	—
May 14, 2025	AMC	—	-0.14	—	54.00	-3.7%	-2.2%	-3.8%	-0.8%	+3.2%	-4.6%	—
Apr 14, 2025	AMC	-1.00	-0.17	+83.0%	44.40	+14.4%	+8.1%	-8.3%	+10.0%	+5.8%	+6.2%	—
Nov 19, 2024	AMC	-0.60	-9.60	-1500.0%	62.80	+7.0%	-6.4%	-15.6%	+4.8%	-20.8%	+10.7%	—
Aug 19, 2024	AMC	-1.00	-3.20	-220.0%	144.00	-6.4%	-0.3%	+0.0%	+3.3%	+3.5%	-1.0%	—
May 15, 2024	AMC	-1.00	-3.20	-220.0%	58.40	-1.4%	+1.4%	+2.7%	+0.0%	+7.9%	+16.5%	—
Mar 29, 2024	AMC	—	-2.40	—	—	—	—	—	—	—	—	—
Oct 3, 2023	AMC	-0.60	-2.40	-300.0%	153.60	-4.9%	-5.2%	+0.0%	+1.7%	-0.9%	-2.7%	—
Sep 26, 2023	AMC	-1.00	2.00	+300.0%	162.00	-6.9%	+0.0%	+0.7%	-3.2%	-8.6%	+6.3%	—
Jul 19, 2023	AMC	-0.07	-0.10	-42.9%	140.80	-1.7%	-0.6%	-0.6%	+0.0%	+8.0%	+4.3%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 8	Maxim Group	Downgrade	Buy → Hold	—	$3.80	$3.78	-0.5%	+2.1%	+1.0%	-2.3%	+11.0%	+8.9%
Apr 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.15	$5.15	+0.0%	-9.7%	-3.9%	-20.8%	+7.3%	+2.1%
Sep 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$34.00	$35.44	+4.2%	-1.2%	-6.0%	-2.5%	+2.5%	-1.7%
Dec 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$431.20	$460.00	+6.7%	+3.7%	-3.4%	+5.6%	-7.0%	-0.8%
Nov 1	Alliance Global Partners	Maintains	Buy → Buy	—	$372.80	$380.00	+1.9%	+1.1%	+4.0%	+0.0%	-0.4%	+0.4%
Mar 13	B. Riley FBR	Maintains	Buy → Buy	—	$1104.00	$1128.00	+2.2%	-8.7%	-15.9%	+18.9%	-2.1%	+2.8%
Mar 13	B. Riley Securities	Maintains	Buy → Buy	—	$1104.00	$1128.00	+2.2%	-8.7%	-15.9%	+18.9%	-2.1%	+2.8%
Mar 12	B. Riley Securities	Maintains	Buy → Buy	—	$1233.60	$1200.00	-2.7%	-10.5%	-8.7%	-15.9%	+18.9%	-2.1%
May 5	B. Riley FBR	Maintains	Neutral → Neutral	—	—	—	—	—	—	—	—	—
Mar 29	Canaccord Genuity	Maintains	Buy → Buy	—	$1416.00	$1408.00	-0.6%	+2.8%	+1.1%	-2.2%	+0.0%	+9.4%
Feb 8	B. Riley FBR	Maintains	Neutral → Neutral	—	$1752.00	$1760.00	+0.5%	+4.6%	+1.3%	+9.9%	-5.5%	+0.4%
Sep 22	William Blair	Upgrade	Market Perform → Outperform	—	$6992.00	$7864.00	+12.5%	-6.4%	-11.0%	-2.3%	-3.4%	-8.2%
May 31	Chardan Capital	Upgrade	Sell → Neutral	—	$4712.00	$4920.00	+4.4%	+4.1%	+1.6%	+7.9%	-9.5%	-1.5%
May 12	William Blair	Downgrade	Outperform → Market Perform	—	$9192.00	$7440.00	-19.1%	-21.4%	+0.9%	-11.4%	-4.8%	-3.4%
May 11	William Blair	Downgrade	Outperform → Perform	—	$8800.00	$8944.00	+1.6%	+4.5%	-21.4%	+0.9%	-11.4%	-4.8%
Apr 17	Chardan Capital	Maintains	Sell → Sell	—	$12816.00	$12088.00	-5.7%	-16.9%	+12.5%	-7.9%	+18.7%	+25.2%
Jul 11	Chardan Capital	Maintains	Sell → Sell	—	$9623.20	$8800.00	-8.6%	-8.1%	+1.4%	+3.6%	-3.2%	-12.7%

Data updated apr 26, 2026 9:31am · Source: massive.com